Publications by authors named "Gill A Webster"

Claim this Profile
F
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Mikiya Ishihara, Yasutaka Tono, Yoshihiro Miyahara, Daisuke Muraoka, Naozumi Harada, Gill A Webster

Cancer Immunol Immunother· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate signaling within the central nervous system recruits protective neutrophils.
Reza Khorooshi, Joanna Marczynska, Ruthe Storgaard Dieu, Vian Wais, Christian Rønn Hansen, Gill A Webster

Acta Neuropathol Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIS416 Enhances Therapeutic Functions of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Against Experimental Colitis by Modulating Systemic Immune Milieu.
Byung-Chul Lee, Nari Shin, Jin Young Lee, Insung Kang, Jae-Jun Kim, Gill A Webster

Front Immunol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells.
Francesco Mainini, David S Larsen, Gill A Webster, Sarah L Young, Michael R Eccles

Nucleic Acid Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.
Gill A Webster, Dalice A Sim, Anne C La Flamme, Nancy E Mayo

Pilot Feasibility Stud· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging Small Molecules to Modified Bacterial Microparticles Using a Disulphide Linkage: MIS416 as a Cargo Delivery System.
Francesco Mainini, David S Larsen, Gill A Webster, Sarah L Young, Michael R Eccles

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Anm Nazmul H Khan, Nonna Kolomeyevskaya, Kelly L Singel, Melissa J Grimm, Kirsten B Moysich, Gill A Webster

Oncotarget· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.
Rebecca C Girvan, Deborah A Knight, Chris J O'Loughlin, Colin M Hayman, Ian F Hermans, Gill A Webster

Vaccine· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with the proto-oncogene c-Myc.
Neil R Chapman, Gill A Webster, Peter J Gillespie, Brian J Wilson, Dorothy H Crouch

Biochem J· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis